Passion. Experience. Diligence.


SeroScience Ltd. was founded in 2006 by a group of world renown immunologists to help pharma and medical device companies overcome adverse immunological side effects to their products, with a particular focus on hypersensitivity reactions and other adverse immunological side effects.  A decade and an international acquisition later, the recently formed SeroScience Group International is proud to offer a wide array of services in the toxicological and immunological sciences space, combining access to state-of-the-art GLP laboratories with consultation by a network of leading international experts in immunology and toxicology. 


Our mission is to bridge the gap between cutting edge research done in academic settings and its industrial application at the GLP level in CROs.  To that end, our reports are reviewed by internationally renown scientists (immunology and drug delivery specialists) as well as certified toxicology experts experts and former FDA advisers, guaranteeing that a comprehensive and multi-dimensional perspective is provided that takes into account both regulatory and academic concerns.


Get in touch

At SeroScience, we know that finding the right CRO is a choice not to be taken lightly. That’s why we offer free consultations to walk you through your needs, the scope of your goals, and your budget.

Book a Consultation ▸




Janos prefered crop.jpg

CEO, Co-Founder

Janos Szebeni

Dr. János Szebeni, MD, PhD, DSc, Med. Habil., immunologist, co-founder and CEO of SeroScience Ltd. is also director of the Nanomedicine Research and Education Center at Semmelweis University in Budapest and full professor of immune biology at Miskolc University in Miskolc, Hungary. He has held various guest professor and scientific positions in Hungary and the United States where he lived for 22 years. His research on various themes in hematology, membrane biology and immunology resulted in over 200 publications including peer-reviewed papers, book chapters, patents, and a book entitled “The Complement System: Novel Roles in Health and Disease” (Kluwer, 2004). He was primary investigator in more than a dozen European and Hungarian research grants and over 30 CRO projects over the past 10 years. Dr. Szebeni is a regular speaker at international conferences and seminars with over 60 presentations in the past five years. He is also an ad hoc consultant for the United States Food and Drug Administration (FDA). Three fields stand out where he has been most active: artificial blood, liposomes and the complement system. His original work led to the CARPA concept, i.e., that complement activation underlies numerous drug-induced (pseudo)allergic infusion reactions. CARPA has been included in a recent European Medicines Agency (EMA) guideline as a recommended preclinical safety test.




Tibor Hejj

Dr. Tibor Héjj, President of the SeroScience Group and responsible for its international sales and operations, is also the Founder and Managing Partner of Proactive Management Consulting (PMC) Ltd., a boutique strategy consulting firm specializing in supporting international operations and communications for multinational companies. He holds an MBA from Vanderbilt University, two M.Sc. degrees from the Technical University of Budapest, and a PhD in management theory from Sophia University in Italy.

Before founding PMC, Dr. Hejj was Country Manager for the Boston Consulting Group (1994-2001) and a Partner/International Vice President at A.T. Kearney (2001-2003). Earlier in his career, he co-founded and served for 10 years as one of the Executive Vice Presidents of Műszertechnika, the most successful Hungarian computer and telecom company of its time, with subsidiaries in Germany, Switzerland, USA and Taiwan.